Clinical potential of nitric oxide-independent soluble guanylate cyclase activators.

@article{Doggrell2005ClinicalPO,
  title={Clinical potential of nitric oxide-independent soluble guanylate cyclase activators.},
  author={Sheila A Doggrell},
  journal={Current opinion in investigational drugs},
  year={2005},
  volume={6 9},
  pages={874-8}
}
A major problem with using nitrates in the treatment of ischemic heart disease is that tolerance develops to their vasodilatory actions. YC-1 was used as the lead compound to synthesize further nitric oxide-independent soluble guanylate cyclase activators, including BAY-41-2272 and BAY-41-8543. A nitric oxide and heme-independent activator of soluble guanylate cyclase, BAY-58-2667, was subsequently discovered by high-throughput screening. Tolerance to the vasodilatory actions of BAY-41-8543 and… CONTINUE READING